Population Council, New York, NY 10065, USA.
Contraception. 2013 Mar;87(3):319-30. doi: 10.1016/j.contraception.2012.08.002. Epub 2012 Sep 17.
Steady progress in contraception research has been achieved over the past 50 years. Hormonal and nonhormonal modern contraceptives have improved women's lives by reducing different health conditions that contributed to considerable morbidity. However, the contraceptives available today are not suitable to all users, and the need to expand contraceptive choices still exists. Novel products such as new implants, contraceptive vaginal rings, transdermal patches and newer combinations of oral contraceptives have recently been introduced in family planning programs, and hormonal contraception is widely used for spacing and limiting births. Concerns over the adverse effects of hormonal contraceptives have led to research and development of new combinations with improved metabolic profile. Recent developments include use of natural compounds such as estradiol and estradiol valerate with the hope to decrease thrombotic risk, in combination with newer progestins derived from the progesterone structure or from spirolactone, in order to avoid the androgenic effects. Progesterone antagonists and progesterone receptor modulators are highly effective in blocking ovulation and preventing follicular rupture and are undergoing investigations in the form of oral pills and in semi-long-acting delivery systems. Future developments also include the combination of a contraceptive with an antiretroviral agent for dual contraception and protection against sexually transmitted diseases, to be used before intercourse or on demand, as well as for continuous use in dual-protection rings. Although clinical trials of male contraception have reflected promising results, limited involvement of industry in that area of research has decreased the likelihood of having a male method available in the current decade. Development of nonhormonal methods is still at an early stage of research, with the identification of specific targets within the reproductive system in ovaries and testes, as well as interactions between spermatozoa and ova. It is hoped that the introduction of new methods with additional health benefits would help women and couples with unmet needs to obtain access to a wider range of contraceptives with improved acceptability.
在过去的 50 年中,避孕研究取得了稳步进展。激素和非激素现代避孕药通过减少导致大量发病的不同健康状况,改善了妇女的生活。然而,目前可用的避孕药并不适合所有使用者,仍然需要扩大避孕选择。最近在计划生育方案中引入了新的植入物、避孕阴道环、透皮贴剂和新型口服避孕药组合等新型产品,激素避孕被广泛用于控制生育间隔和生育数量。对激素避孕药不良反应的担忧导致了具有改善代谢特征的新组合的研究和开发。最近的发展包括使用天然化合物,如雌二醇和雌二醇戊酸,希望降低血栓形成风险,与源自孕激素结构或螺内酯的新型孕激素结合,以避免雄激素作用。孕激素拮抗剂和孕激素受体调节剂在阻断排卵、防止卵泡破裂方面非常有效,正在以口服药丸和半长效递药系统的形式进行研究。未来的发展还包括将避孕药与抗逆转录病毒药物结合,用于双重避孕和预防性传播疾病,可在性交前或按需使用,也可用于双重保护环的连续使用。尽管男性避孕药的临床试验反映了有希望的结果,但由于该领域研究中行业参与有限,减少了在当前十年中提供男性避孕方法的可能性。非激素方法的发展仍处于研究的早期阶段,已经确定了卵巢和睾丸生殖系统内的特定目标,以及精子和卵子之间的相互作用。人们希望引入具有额外健康益处的新方法,将有助于有未满足需求的妇女和夫妇获得更广泛的、接受度更高的避孕方法。